

Resource Summary Report

Generated by [PRECISE-TBI](#) on Sep 8, 2026

SynergyFinder

RRID:SCR_019318

Type: Tool

Proper Citation

SynergyFinder (RRID:SCR_019318)

Resource Information

URL: <https://bioconductor.org/packages/synergyfinder/>

Proper Citation: SynergyFinder (RRID:SCR_019318)

Description: Software R package as efficient implementations for all popular synergy scoring models for drug combinations, including HSA, Loewe, Bliss and ZIP and visualization of synergy scores as either two dimensional or three dimensional interaction surface over dose matrix. Used to calculate and visualize synergy scores for drug combinations.

Synonyms: synergyfinder

Resource Type: data processing software, data visualization software, software application, software resource, software toolkit

Defining Citation: [DOI:10.1007/978-1-4939-7493-1_17](https://doi.org/10.1007/978-1-4939-7493-1_17)

Keywords: Synergy scores, drug combinations, popular synergy scoring models, dimensional interaction surface, dose matrix, bio.tools

Availability: Free, Available for download, Freely available

Resource Name: SynergyFinder

Resource ID: SCR_019318

Alternate IDs: biotools:synergyfinder

Alternate URLs: <https://bio.tools/synergyfinder>

Record Creation Time: 20220129T080344+0000

Record Last Update: 20260905T132848+0000

Ratings and Alerts

No rating or validation information has been found for SynergyFinder.

No alerts have been found for SynergyFinder.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 624 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Liu S, et al. (2026) Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression. Journal for immunotherapy of cancer, 14(2).

Mitchell DK, et al. (2026) Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis. Science advances, 12(5), eady8382.

Kong T, et al. (2026) Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial. Nature communications, 17(1), 949.

Baeten JT, et al. (2026) Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML. Blood advances, 10(7), 2506.

Tiller K, et al. (2026) Reactive oxygen species promotion drives auranofin's antiviral activity against hepatitis E virus. Journal of virology, 100(1), e0191725.

Kono K, et al. (2026) Microtubule Inhibitors Induce Cross-Resistance to Osimertinib Through CaMKII Activation in EGFR-Mutated NSCLC. Cancer science, 117(2), 418.

Li N, et al. (2026) Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma. Blood advances, 10(5), 1722.

Uras IZ, et al. (2026) KRAS mutated lung adenocarcinoma responds to pan-ERBB and Aurora kinase inhibitors. NPJ precision oncology, 10(1), 14.

Pereira-Martins DA, et al. (2026) ?Np73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia. Cell reports. Medicine, 102540.

Pang H, et al. (2026) TIP-20, a novel feline McDonough sarcoma-like tyrosine kinase 3 inhibitor with potent antileukemia activity. The Journal of international medical research, 54(2), 3000605251412963.

Wen E, et al. (2026) AUM-302, a novel triple PIM/PI3K/mTOR inhibitor, synergizes with RAS inhibition and impedes the growth of pancreatic ductal adenocarcinoma spheroids and organoids. *Frontiers in pharmacology*, 17, 1685433.

Siváková A, et al. (2026) The combination of mupirocin and Kayvirus broadens the decolonization effect against *Staphylococcus aureus*. *Applied microbiology and biotechnology*, 110(1).

Faust JR, et al. (2026) Mesothelin promotes acute myeloid leukemia progression through LYN-dependent signaling. *The Journal of biological chemistry*, 302(5), 111390.

Franceschi S, et al. (2026) BIRC3/CAV1 co-expression drives GBM aggressiveness as a prognostic signature and therapeutic vulnerability. *Cell death discovery*, 12(1).

Nguyen TQA, et al. (2026) Targeting RNase H2: A dual-mechanism strategy to elevate replication stress, DNA damage, and antitumor immunity in TNBC. *Cell reports. Medicine*, 7(5), 102750.

Zhang L, et al. (2026) HDAC8 inhibition targets STAT3-MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia. *Leukemia*, 40(6), 1271.

Buzo K, et al. (2026) WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer. *EMBO molecular medicine*, 18(6), 2322.

Subramani E, et al. (2026) Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers. *iScience*, 29(6), 116184.

Maass P, et al. (2026) Venetoclax and hypomethylating agents synergize to increase cell death and metabolic remodeling in acute B-lymphoblastic leukemia cells. *Molecular metabolism*, 110, 102402.

Shi M, et al. (2026) Dual Metabolic Inhibition by Berberine and Glutor Triggers AMPK/JNK-Dependent DNA Damage in Cancer Cells. *International journal of medical sciences*, 23(7), 2355.